Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2023

	*June 30,*		*December 31,*
	*2023*		*2022*
Research and development fees	$	3,847	$	5,758
Compensation expense		2,125		3,015
Accrued accounts payable		1,531		1,245
Lease liabilities		910		859
Other current liabilities		497		483
Accrued license obligations		172		245
Total	$	9,082	$	11,605